Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q33403826

about

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro Bosutinib in the management of chronic myelogenous leukemia.Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Bosutinib for Chronic Myeloid Leukemia.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

P2860

Q27004032-C73397B6-45D4-4CEE-8392-20A50FFBC012 Q37026032-27B8D758-E58A-43FF-B7C0-7167277CC822 Q37140624-F04536BB-A559-45B8-A00C-5333C219AEE6 Q38106952-98035B5E-AB7F-49C3-9D78-C8D055A00BBA Q38178192-E7C3FDC9-7969-42C8-83D6-693069993FDD Q38817367-DE532C61-E16A-4BF9-BC9B-0001ADDEDEB3 Q38835127-B6C029F1-3D33-45A1-A5B1-A27157DF8083 Q39116591-97E8840F-A884-4B85-9EE3-69DBEEB51E09 Q39429946-BA9E05CA-D6FC-4844-8367-9C4FDFFB18B3 Q51415497-653E6000-67EF-4EB0-A5D7-0B4AA6550DCC Q52571134-963A34EF-FDA2-43D9-95B2-AEDD1FA82BA3

P2860

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q33403826

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@ast

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@en

type

label

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@ast

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@en

prefLabel

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@ast

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@en

P1433

Q33403826-A7170DA0-6393-47FF-858C-9EC2FD18ABEE

P1476

Q33403826-C9855EEE-DFE0-48CD-9720-94C65F829924

P2093

Q33403826-42AF4B84-DFE8-427D-B221-48711B06ADA7

Q33403826-48F6DC89-C757-4071-9A21-0C3F22F9A6CB

Q33403826-AE98D0B8-90D3-44D0-9451-9F37A195223C

P2860

Q33403826-0DF026AF-9520-44DE-9778-36CFD4278A62

Q33403826-43370D0E-C427-4C14-A746-29CF32B73386

Q33403826-4A1B668E-BC9C-4A4C-B949-F313653BBBA7

Q33403826-5363C563-21A8-4933-B7A0-2FC51505EBD7

Q33403826-61FB41CE-FEE4-420F-9610-79EEAF7E92D4

Q33403826-75D5C401-3D1C-4C15-AA7F-6B7EB4652A08

Q33403826-8664E54B-8AAC-4D15-A267-348E58F44C3A

Q33403826-96290C74-6F5F-4603-B43C-1C142FCEC7BF

Q33403826-E1D29E98-DA07-4DE7-A562-947FDF09A082

Q33403826-E82D2283-47F4-4731-9CEE-137962CFF931

P2888

Q33403826-D33C1E75-C287-4B2F-BF2A-9C7E91F67396

P304

Q33403826-33DC1B0D-1BC2-482E-A26E-B8974910245F

P31

Q33403826-12C5E725-6EBE-4900-9F6D-46D10B15A870

Q33403826-84663717-9a4c-493c-8e97-7214631dd5c1

P356

Q33403826-B03293EF-FDF4-4EDE-8674-B1F8BB2540BE

P433

Q33403826-AB0E0007-E193-42EF-B129-B48F10966051

P478

Q33403826-B38655D5-76A2-43CE-89E2-5DAEEC6B9D64

P50

Q33403826-3A7902D9-AB18-4857-85AE-78C29792A698

P577

Q33403826-146A71C1-2F0B-418E-B078-256D7328B6EE

P5875

Q33403826-EC8D626F-3810-4E9F-AD19-3C316C45A3F7

P6179

Q33403826-B1600E0E-A1B4-4316-8429-FD00D6015D45

P698

Q33403826-4A0D8F22-BD88-4480-B776-887DFF9E4E9A

P921

Q33403826-32DDBD4B-116E-4A32-A55F-3E9BB17FBAFE

Q33403826-B256E867-3F7E-4CA9-B186-E0CBABABC3B0

P356

S00280-012-1998-4

P1433

Cancer Chemotherapy and Pharmacology

P1476

Pharmacokinetic-pharmacodynami ...... hase chronic myeloid leukemia.

@en

P2093

Diane R Mould

http://www.w3.org/2001/XMLSchema#string

Michael Amantea

http://www.w3.org/2001/XMLSchema#string

Poe-Hirr Hsyu

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

P2888

s00280-012-1998-4

P304

209-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-012-1998-4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Richard N Upton

P577

2012-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232255864

http://www.w3.org/2001/XMLSchema#string

P6179

1029197185

http://www.w3.org/2001/XMLSchema#string

P698

23070145

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia